查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405853

神經生物標記市場規模、佔有率、趨勢分析報告：按應用、類型、最終用途、地區和細分市場預測，2024-2030 年

Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type, By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

神經生物標記物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球神經生物標記市場規模將達到187.5億美元，2024年至2030年複合年成長率為12.89%。

增加神經生物標記研發資金以促進開發新藥預計將推動市場成長。美國國家神經疾病和中風研究所為進行臨床檢驗、分析檢驗和生物標記發現相關研究的研究人員提供資助機會，包括合作研究協議和開發津貼。

生物標記在治療神經系統疾病的藥物開發中發揮重要作用。近年來，神經系統疾病治療方法的研發投入大幅增加。例如，2020 年 12 月，非營利研究基金會 Target ALS 宣佈為專注於發現 ALS 新型生物標記的計劃提供 1500 萬美元的研究經費，並預測在此期間市場成長預計將加速。

隨著Quanterix Simoa（單分子陣列）等技術先進產品的出現，這是一種具有高信噪比的數位化ELISA 測試。該技術可以幫助克服與神經系統疾病相關生物標記相關的血腦障壁問題。預計此類技術進步將推動市場成長。例如，2021 年 1 月，雅培宣布首次針對創傷性腦損傷（包括腦震盪）進行快速血液檢測。此測試測量腦外傷後血液中發現的特定蛋白質，如果測試結果呈陰性，可用於排除電腦斷層掃描的需要。

特別是在開發中國家，對此類診斷產品缺乏認知、高成本以及神經科的可用性有限或缺乏等因素阻礙了此類基於生物標記的診斷解決方案的採用，可能會產生影響。根據世界神經病學聯合會對 63/84 個 WHO 成員國的調查，31/63 個國家的大多數神經科都在大城市。一名神經科為大約 6,240 至 4,750,000 人提供服務。

神經生物標記物市場報告亮點

  • 蛋白質體學在 2023 年佔據最大的市場佔有率，預計在預測期內將保持其主導地位。蛋白質體學對於準確診斷疾病的發病和進展至關重要，因為它們會仔細檢測轉譯後修飾和蛋白質特徵。
  • 由於患病率上升以及研發活動的活性化，帕金森氏症領域佔據了最大的市場佔有率。
  • 從最終用途來看，研究機構和其他領域主導了神經生物標記市場。研究機構合作開發治療神經系統疾病的藥物，使用生物標記來評估抗藥性。
  • 由於美國和加拿大市場參與者的強大影響力以及政府對新型生物標記開發的資助不斷增加，北美在市場上佔據主導地位。
  • 由於日本和澳洲等已開發國家以及中國和印度等新興經濟體擴大採用技術先進的診斷產品，亞太地區將在預測期內繼續成長，預計將顯著成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章神經生物標記市場變數、趨勢與範圍

  • 神經生物標記市場預測
    • 母市場展望
  • 繪製普及和成長前景圖
  • 管道分析
    • 阿茲海默症
    • 帕金森氏症
    • 多發性硬化症
    • 泛自閉症障礙
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 神經生物標記：市場分析工具
    • 產業分析-波特五力分析
    • PESTLE分析

第 4 章 神經生物標記市場：細分分析（按類型），2018-2030

  • 神經生物標記市場：類型變異分析
    • 基因組
    • 蛋白質體學
    • 代謝組學
    • 影像
    • 其他

第 5 章 神經生物標記市場：細分分析（按應用），2018-2030

  • 神經生物標記市場：應用變化分析
    • 阿茲海默症
    • 帕金森氏症
    • 多發性硬化症
    • 泛自閉症障礙
    • 其他

第 6 章 神經生物標記市場：細分分析，依最終用途，2018-2030

  • 神經生物標記市場：最終用途變異分析
    • 醫院和醫院實驗室
    • 獨立臨床診斷中心
    • 調查組織等

第 7 章 神經生物標記市場：細分分析，按地區，2018-2030

  • 區域市場簡介
  • 北美洲
    • 北美神經生物標記市場，2018-2030
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲神經生物標記市場，2018-2030
    • 英國
    • 德國
    • 西班牙
    • 法國
    • 義大利
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 亞太地區神經生物標記市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 韓國
    • 泰國
    • 澳洲
  • 拉丁美洲
    • 拉丁美洲神經生物標記市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 中東和非洲神經生物標記市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章神經生物標記市場：競爭分析

  • 公司分類
  • 策略規劃
    • 新產品發布
    • 合夥
    • 獲得
    • 合作
    • 資金籌措
  • 2022 年公司市場佔有率分析
  • 公司簡介
    • Abbott
    • Johnson &Johnson Services, Inc.
    • Bio-rad Laboratories, Inc.
    • Alseres Pharmaceuticals, Inc.
    • Banyan Biomarkers, Inc.
    • Rules-based Medicine
    • Thermo Fisher Scientific, Inc.
    • Diagenic Asa
    • Merck &Co., Inc.
    • Quanterix
Product Code: GVR-3-68038-823-7

Neurological Biomarkers Market Growth & Trends:

The global neurological biomarkers market size is expected to reach USD 18.75 billion by 2030, expanding at a CAGR of 12.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increased funding for R&D of neurological biomarkers to boost development of new drugs is expected to impel market growth. National Institute of Neurological Disorders and Stroke provides funding opportunities such as cooperative agreements & development grants for researchers conducting studies related to clinical validation, analytical validation, & biomarker discovery.

Biomarkers play a significant role in the development of drugs for the treatment of neurological diseases. In recent years, there has been a significant rise in investments in the R&D of treatments for neurological diseases. For instance, in December 2020, Target ALS-a nonprofit research foundation-announced research funding of USD 15 million for a project focused on the discovery of novel biomarkers for ALS, which is anticipated to accelerate market growth in the forecast period.

Availability of technologically advanced products such as Quanterix Simoa (single-molecule array), which is a digitized ELISA test with a high signal-to-noise ratio. This technology helps overcome blood-brain barrier issues associated with neurological disease-related biomarkers. Such technological advancements are expected to drive market growth. For instance, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Factors such as lack of awareness about such diagnostic products & their high cost and limited availability or absence of neurologists, especially in developing & underdeveloped countries, could affect the adoption of such biomarker-based diagnostic solutions. According to a World Federation of Neurology survey of 63/84 WHO member countries, the majority of neurologists in 31/63 countries worked in major cities. One neurologist was serving a population of about 6,240 to 4,750,000.

Neurological Biomarkers Market Report Highlights:

  • In 2023, proteomic type accounted for the largest market share and is anticipated to maintain their dominance over the forecast period as these are essential for accurate diagnosis of disease onset and progression due to the careful detection of posttranslational modifications and protein signatures
  • Parkinson's disease segment held the largest market share owing to rising incidence and increasing R&D activities.
  • Based on end use, the research organizations and others segment dominated the neurological biomarkers market. Research organizations collaborating for the development of therapeutics for treating neurological disorders utilize biomarkers for assessing the drug tolerance.
  • North America dominated the market owing to presence of market players with strong presence in the U.S. & Canada, and increasing government funding for the development of novel biomarkers
  • Asia-Pacific is anticipated to witness significant growth over the forecast period owing to high adoption of technologically advanced diagnostic products in developed countries such as Japan & Australia and increasing adoption of these products in developing economies such as China and India.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation And Scope
    • 1.1.1 Segment Definition
      • 1.1.1.1 Application Segment
      • 1.1.1.2 Type Segment
      • 1.1.1.3 End Use Segment
  • 1.2 Regional Scope
  • 1.3 Estimates And Forecast Timeline
  • 1.4 Objectives
    • 1.4.1 Objective - 1
    • 1.4.2 Objective - 2
    • 1.4.3 Objective - 3
  • 1.5 Research Methodology
  • 1.6 Information Procurement
    • 1.6.1 Purchased Database
    • 1.6.2 GVR's Internal Database
    • 1.6.3 Secondary Sources
    • 1.6.4 Primary Research
  • 1.7 Information Or Data Analysis
    • 1.7.1 Data Analysis Models
  • 1.8 Market Formulation & Validation
  • 1.9 Model Details
    • 1.9.1 Commodity Flow Analysis
  • 1.10 List Of Secondary Sources
  • 1.11 List Of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Application And Type Snapshot
  • 2.3 End Use Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Neurological Biomarkers Market Variables, Trends, And Scope

  • 3.1 Neurological Biomarkers Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Penetration And Growth Prospect Mapping
  • 3.3 Pipeline Analysis
    • 3.3.1 Alzheimer's Disease
    • 3.3.2 Parkinson's Disease
    • 3.3.3 Multiple Sclerosis
    • 3.3.4 Autism Spectrum Disorder
  • 3.4 Market Dynamics
    • 3.4.1 Market Driver Analysis
      • 3.4.1.1 Increasing Prevalence Of Neurological Diseases
      • 3.4.1.2 Technological Advancements
      • 3.4.1.3 Increased Funding For R&d In Biomarkers
    • 3.4.2 Market Restraint Analysis
      • 3.4.2.1 Lack Of Consumer Awareness
      • 3.4.2.2 Reimbursement Policies
  • 3.5 Neurological Biomarkers: Market Analysis Tools
    • 3.5.1 Industry Analysis - Porter's Five Forces
    • 3.5.2 Pestle Analysis

Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

  • 4.1 Neurological Biomarkers Market: Type Movement Analysis
    • 4.1.1 Genomic
      • 4.1.1.1 Genomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.2 Proteomic
      • 4.1.2.1 Proteomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.3 Metabolomic
      • 4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.5 Imaging
      • 4.1.5.1 Imaging Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 4.1.6 Others
      • 4.1.6.1 Other Neurological Biomarkers Market, 2018 - 2030 (USD Million)

Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 5.1 Neurological Biomarkers Market: Application Movement Analysis
    • 5.1.1 Alzheimer's Disease
      • 5.1.1.1 Alzheimer's Disease Market, 2018 - 2030 (USD Million)
    • 5.1.2 Parkinson's Disease
      • 5.1.2.1 Parkinson's Disease Market, 2018 - 2030 (USD Million)
    • 5.1.3 Multiple Sclerosis
      • 5.1.3.1 Multiple Sclerosis Market, 2018 - 2030 (USD Million)
    • 5.1.4 Autism Spectrum Disorder
      • 5.1.4.1 Autism Spectrum Disorder Market, 2018 - 2030 (USD Million)
    • 5.1.5 Others
      • 5.1.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End-use, 2018 - 2030 (USD Million)

  • 6.1 Neurological Biomarkers Market: End-use Movement Analysis
    • 6.1.1 Hospital & Hospital Laboratories
      • 6.1.1.1 Hospitals & Hospital Laboratories Market, 2018 - 2030 (USD Million)
    • 6.1.2 Independent Clinical Diagnostic Centers
      • 6.1.2.1 Independent Clinical Diagnostic Centers Market, 2018 - 2030 (USD Million)
    • 6.1.3 Research Organizations And Others
      • 6.1.3.1 Research Organizations And Others Market, 2018 - 2030 (USD Million)

Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

  • 7.1 Regional Market Snapshot
  • 7.2 North America
    • 7.2.1 North America Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 U.S. Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.2.2 Key Country Dynamics
      • 7.2.2.3 Regulatory Framework
      • 7.2.2.4 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Canada Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.2.3.2 Key Country Dynamics
      • 7.2.3.3 Regulatory Framework
      • 7.2.3.4 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.2 UK
      • 7.3.2.1 UK Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.2.2 Key Country Dynamics
      • 7.3.2.3 Regulatory Framework
      • 7.3.2.4 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Germany Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.3.2 Key Country Dynamics
      • 7.3.3.3 Regulatory Framework
      • 7.3.3.4 Reimbursement Scenario
    • 7.3.4 Spain
      • 7.3.4.1 Spain Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.4.2 Key Country Dynamics
      • 7.3.4.3 Regulatory Framework
      • 7.3.4.4 Reimbursement Scenario
    • 7.3.5 France
      • 7.3.5.1 France Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.5.2 Key Country Dynamics
      • 7.3.5.3 Regulatory Framework
      • 7.3.5.4 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Italy Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.6.2 Key Country Dynamics
      • 7.3.6.3 Regulatory Framework
      • 7.3.6.4 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Denmark Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.7.2 Key Country Dynamics
      • 7.3.7.3 Regulatory Framework
      • 7.3.7.4 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Sweden Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.8.2 Key Country Dynamics
      • 7.3.8.3 Regulatory Framework
      • 7.3.8.4 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Norway Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.3.9.2 Key Country Dynamics
      • 7.3.9.3 Regulatory Framework
      • 7.3.9.4 Reimbursement Scenario
  • 7.4 Asia Pacific
    • 7.4.1 Asia-pacific Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Japan Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.2.2 Key Country Dynamics
      • 7.4.2.3 Regulatory Framework
      • 7.4.2.4 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 China Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.3.2 Key Country Dynamics
      • 7.4.3.3 Regulatory Framework
      • 7.4.3.4 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 India Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.4.2 Key Country Dynamics
      • 7.4.4.3 Regulatory Framework
      • 7.4.4.4 Reimbursement Scenario
    • 7.4.5 South Korea
      • 7.4.5.1 South Korea Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.5.2 Key Country Dynamics
      • 7.4.5.3 Regulatory Framework
      • 7.4.5.4 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Thailand Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.6.2 Key Country Dynamics
      • 7.4.6.3 Regulatory Framework
      • 7.4.6.4 Reimbursement Scenario
    • 7.4.7 Australia
      • 7.4.7.1 Australia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.4.7.2 Key Country Dynamics
      • 7.4.7.3 Regulatory Framework
      • 7.4.7.4 Reimbursement Scenario
  • 7.5 Latin America
    • 7.5.1 Latin America Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Brazil Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.2.2 Key Country Dynamics
      • 7.5.2.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.3 Mexico
      • 7.5.3.1 Mexico Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.3.2 Key Country Dynamics
      • 7.5.3.3 Regulatory Framework
      • 7.5.2.4 Reimbursement Scenario
    • 7.5.4 Argentina
      • 7.5.4.1 Argentina Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.5.4.2 Key Country Dynamics
      • 7.5.4.3 Regulatory Framework
      • 7.5.4.4 Reimbursement Scenario
  • 7.6 MEA
    • 7.6.1 MEA Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 South Africa Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.2.2 Key Country Dynamics
      • 7.6.2.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.3.2 Key Country Dynamics
      • 7.6.3.3 Regulatory Framework
      • 7.6.3.4 Reimbursement Scenario
    • 7.6.4 UAE
      • 7.6.4.1 UAE Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.4.2 Key Country Dynamics
      • 7.6.4.3 Regulatory Framework
      • 7.6.2.4 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Kuwait Neurological Biomarkers Market, 2018 - 2030 (USD Million)
      • 7.6.5.2 Key Country Dynamics
      • 7.6.5.3 Regulatory Framework
      • 7.6.5.4 Reimbursement Scenario

Chapter 8 Neurological Biomarkers Market: Competitive Analysis

  • 8.1 Company Categorization
  • 8.2 Strategy Mapping
    • 8.2.1 New Product Launches
    • 8.2.2 Partnerships
    • 8.2.3 Acquisitions
    • 8.2.4 Collaborations
    • 8.2.5 Funding
  • 8.3 Company Market Share Analysis, 2022
  • 8.4 Company Profiles
    • 8.4.1 Abbott
      • 8.4.1.1 Company Overview
      • 8.4.1.2 Financial Performance
      • 8.4.1.3 Product Benchmarking
      • 8.4.1.4 Strategic Initiatives
    • 8.4.2 Johnson & Johnson Services, Inc.
      • 8.4.2.1 Company Overview
      • 8.4.2.2 Financial Performance
      • 8.4.2.3 Product Benchmarking
      • 8.4.2.4 Strategic Initiatives
    • 8.4.3 Bio-rad Laboratories, Inc.
      • 8.4.3.1 Company Overview
      • 8.4.3.2 Financial Performance
      • 8.4.3.3 Product Benchmarking
      • 8.4.3.4 Strategic Initiatives
    • 8.4.4 Alseres Pharmaceuticals, Inc.
      • 8.4.4.1 Company Overview
      • 8.4.4.2 Product Benchmarking
    • 8.4.5 Banyan Biomarkers, Inc.
      • 8.4.5.1 Company Overview
      • 8.4.5.2 Product Benchmarking
      • 8.4.5.3 Strategic Initiatives
    • 8.4.6 Rules-based Medicine
      • 8.4.6.1 Company Overview
      • 8.4.6.2 Financial Performance
      • 8.4.6.3 Product Benchmarking
      • 8.4.6.4 Strategic Initiatives
    • 8.4.7 Thermo Fisher Scientific, Inc.
      • 8.4.7.1 Company Overview
      • 8.4.7.2 Financial Performance
      • 8.4.7.3 Product Benchmarking
      • 8.4.7.4 Strategic Initiatives
    • 8.4.8 Diagenic Asa
      • 8.4.8.1 Company Overview
      • 8.4.8.2 Product Benchmarking
    • 8.4.9 Merck & Co., Inc.
      • 8.4.9.1 Company Overview
      • 8.4.9.2 Financial Performance
      • 8.4.9.3 Product Benchmarking
      • 8.4.9.4 Strategic Initiatives
    • 8.4.10 Quanterix
      • 8.4.10.1 Company Overview
      • 8.4.10.2 Product Benchmarking
      • 8.4.10.3 Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 3 North America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 5 U.S. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 7 U.S. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 8 Canada neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 10 Canada neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 11 Europe neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 13 Europe neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 14 U.K. neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 15 U.K. neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 16 U.K. neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 17 Germany neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 18 Germany neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 19 Germany neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 20 France neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 21 France neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 22 France neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 23 Italy neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 24 Italy neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 25 Italy neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 26 Spain neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 27 Spain neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 28 Spain neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 29 Denmark neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 30 Denmark neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 31 Denmark neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 32 Sweden neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 33 Sweden neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 34 Sweden neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 35 Norway neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 36 Norway neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 37 Norway neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 41 Japan neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 42 Japan neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 43 Japan neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 44 China neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 45 China neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 46 China neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 47 India neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 48 India neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 49 India neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 50 South Korea neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 51 South Korea neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 52 South Korea neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 53 Australia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 54 Australia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 55 Australia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 56 Thailand neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 57 Thailand neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 58 Thailand neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 59 Latin America neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 60 Latin America neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 61 Latin America neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 62 Brazil neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 63 Brazil neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 64 Brazil neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 65 Mexico neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 66 Mexico neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 67 Mexico neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 68 Argentina neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 69 Argentina neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 70 Argentina neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 71 MEA neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 72 MEA neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 73 MEA neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 74 South Africa neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 75 South Africa neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 76 South Africa neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 77 Saudi Arabia neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 78 Saudi Arabia neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 80 UAE neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 81 UAE neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 82 UAE neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)
  • Table 83 Kuwait neurological biomarkers market, by application, 2018 - 2030 (USD Million)
  • Table 84 Kuwait neurological biomarkers market, by type, 2018 - 2030 (USD Million)
  • Table 85 Kuwait neurological biomarkers market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Neurological biomarkers market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot (Type and application)
  • Fig. 11 Segment snapshot (End-use)
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Biomarkers market value, 2023 (USD Million)
  • Fig. 14 Neurological biomarkers market dynamics
  • Fig. 15 Prevalence of Alzheimer's disease by age group, 2023
  • Fig. 16 Neurological biomarkers market: Porter's Five Forces analysis
  • Fig. 17 Neurological biomarkers market: PESTLE analysis
  • Fig. 18 Neurological biomarkers market: Type outlook and key takeaways
  • Fig. 19 Neurological biomarkers market: Type movement analysis
  • Fig. 20 Genomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Proteomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Metabolomic neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Imaging market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Other neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Neurological biomarkers market: Application outlook and key takeaways
  • Fig. 26 Neurological biomarkers market: Application movement analysis
  • Fig. 27 Alzheimer's disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Parkinson's disease market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Multiple sclerosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Autism spectrum disorder market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Neurological biomarkers market: End-use outlook and key takeaways
  • Fig. 33 Neurological biomarkers market: End-use movement analysis
  • Fig. 34 Hospitals & hospital laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Independent clinical diagnostic centers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Research organizations and others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Neurological biomarkers market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Key country dynamics
  • Fig. 41 U.S. neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Target disease prevalence
  • Fig. 43 Key country dynamics
  • Fig. 44 Canada neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Target disease prevalence
  • Fig. 46 Europe neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 UK neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Germany neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Target disease prevalence
  • Fig. 52 Key country dynamics
  • Fig. 53 France neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Italy neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Spain neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Denmark neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Sweden neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 Norway neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Target disease prevalence
  • Fig. 65 Rest of Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Asia Pacific neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Japan neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Target disease prevalence
  • Fig. 70 Key country dynamics
  • Fig. 71 China neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 Key country dynamics
  • Fig. 73 India neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Target disease prevalence
  • Fig. 75 Key country dynamics
  • Fig. 76 Australia neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Thailand neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 South Korea neurological biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 81 Rest of Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Brazil neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Mexico neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Argentina neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Rest of Latin America neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 South Africa neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Target disease prevalence
  • Fig. 94 Key country dynamics
  • Fig. 95 Saudi Arabia neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Target disease prevalence
  • Fig. 97 Key country dynamics
  • Fig. 98 UAE neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Target disease prevalence
  • Fig. 100 Key country dynamics
  • Fig. 101 Kuwait neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Target disease prevalence
  • Fig. 103 Key payors in Kuwait
  • Fig. 104 Rest of MEA neurological biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key company categorization
  • Fig. 106 Company market positioning
  • Fig. 107 Company market share analysis, 2023
  • Fig. 108 Strategic framework